ESMO – European Society for Medical Oncology shared on LinkedIn:
“For ESMO members: Breaking Science in Gastrointestinal Cancers.
Giovanni Randon presents Switch maintenance with ramucirumab plus paclitaxel in advanced HER2-negative gastric/GEJ cancer.
Discover this video and more in the series on OncologyPRO now.”
Source: ESMO/LinkedIn